Production (Stage)
Collegium Pharmaceutical, Inc.
COLL
$29.71
$0.531.82%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -52.95% | 43.68% | 882.63% | 995.02% | 417.77% |
| Total Depreciation and Amortization | 29.97% | 13.34% | -2.63% | -6.20% | -4.18% |
| Total Amortization of Deferred Charges | -31.07% | -30.33% | -27.61% | -20.50% | -15.85% |
| Total Other Non-Cash Items | 17.37% | -66.81% | -51.56% | -48.51% | -58.45% |
| Change in Net Operating Assets | -258.79% | -352.99% | -255.95% | -103.36% | 1,006.15% |
| Cash from Operations | -35.78% | -25.39% | -27.66% | 17.00% | 74.37% |
| Capital Expenditure | -120.63% | -258.35% | -0.73% | 16.96% | 49.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 88.75% | 73.61% | 28.86% | -31.74% | -- |
| Cash from Investing | -214.67% | -306.37% | -545.36% | -30.29% | -5,152.31% |
| Total Debt Issued | 5,459.36% | 34.58% | 35.81% | -97.33% | -97.52% |
| Total Debt Repaid | -50.53% | -1.50% | -19.64% | 16.54% | 23.18% |
| Issuance of Common Stock | -11.15% | 21.67% | 11.13% | 13.75% | -24.06% |
| Repurchase of Common Stock | 13.09% | 5.00% | -20.22% | -482.56% | -294.01% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -97.13% | -88.30% | -- | -- | -- |
| Cash from Financing | 87.93% | 56.77% | 11.23% | -874.87% | -1,960.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -165.67% | -324.88% | -258.31% | -169.49% | -126.03% |